Targeting PDGF Signaling in Cervical Cancer
Author Information
Author(s): Pietras Kristian, Pahler Jessica, Bergers Gabriele, Hanahan Douglas
Primary Institution: University of California San Francisco
Hypothesis
Pharmacological targeting of stromal support functions, particularly those of cancer-associated fibroblasts, could have therapeutic utility in cervical cancer.
Conclusion
Targeting PDGF receptor signaling in cancer-associated fibroblasts can slow the progression of cervical cancer and impair tumor growth.
Supporting Evidence
- Imatinib treatment reduced the incidence of cervical carcinomas from 80% to 47%.
- Median tumor volume decreased by 61% following imatinib treatment.
- Imatinib treatment lowered the cell proliferation index and increased the apoptotic index in tumors.
Takeaway
Researchers found that blocking a specific signal in tumor-supporting cells can help slow down cervical cancer in mice.
Methodology
The study used a genetically engineered mouse model of cervical cancer to investigate the effects of PDGF receptor signaling inhibition using imatinib.
Limitations
The study was conducted in a mouse model, which may not fully replicate human cervical cancer.
Participant Demographics
HPV/E2 mice, a genetically engineered mouse model.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website